Table 2 Clinical characteristics of the population with high and low Radiomics score groups
From: CT-based machine learning radiomics predicts CCR5 expression level and survival in ovarian cancer
Variables | Total (n = 89) | Low (n = 19) | High (n = 70) | p |
|---|---|---|---|---|
Age, n (%) | ||||
 <65 | 57 (64) | 9 (47) | 48 (69) | 0.15 |
 ≥65 | 32 (36) | 10 (53) | 22 (31) |  |
Chemotherapy, n (%) | ||||
 NO | 4 (4) | 2 (11) | 2 (3) | 0.199 |
 YES | 85 (96) | 17 (89) | 68 (97) |  |
FIGO, n (%) | ||||
 II/III | 47 (53) | 8 (42) | 39 (56) | 0.427 |
 IV/Unknown | 42 (47) | 11 (58) | 31 (44) |  |
Lymphatic invasion, n (%) | ||||
 NO/Unknown | 66 (74) | 13 (68) | 53 (76) | 0.56 |
 YES | 23 (26) | 6 (32) | 17 (24) |  |
Neoplasm histologic grade, n (%) | ||||
 G1/G2 | 9 (10) | 2 (11) | 7 (10) | 1 |
 G3/GX | 80 (90) | 17 (89) | 63 (90) |  |
Radiotherapy, n (%) | ||||
 NO | 86 (97) | 18 (95) | 68 (97) | 0.518 |
 YES | 3 (3) | 1 (5) | 2 (3) |  |
Tumor residual disease, n (%) | ||||
 No/Unknown | 32 (36) | 7 (37) | 25 (36) | 1 |
 YES | 57 (64) | 12 (63) | 45 (64) |  |
Venous invasion, n (%) | ||||
 NO/Unknown | 73 (82) | 17 (89) | 56 (80) | 0.506 |
 YES | 16 (18) | 2 (11) | 14 (20) |  |